Platinum‐based chemotherapy in advanced triple‐negative breast cancer: A multicenter real‐world study in China

Platinum‐based chemotherapy (PBC) has proven benefits in phase III studies for advanced triple‐negative breast cancer (TNBC) patients; however, real‐world data of large samples from multiple centers are lacking. Our study was to compare the effectiveness of PBC and non‐PBC in advanced TNBC patients in multicenter real‐world settings. Totally, 495 patients with advanced TNBC receiving PBC (n = 350) or non‐PBC (n = 145) at four cancer centers in China between 2003 and 2019 were included. Treatment responses and outcomes were compared between the two groups from first‐line to third‐line treatment. Of patients with PBC, 249 (71.1%) received PBC from first‐line chemotherapy, 86 (24.6%) from second‐line and 15 (4.3%) from third‐line treatment. In first‐line treatment, PBC was superior to non‐PBC in objective response rate (ORR, 53.0% vs 32.1%, P < .001) and median progression‐free survival (PFS, 8.4 vs 6.0 months, P = .022), whereas overall survival (OS) was similar (19.2 vs 16.8 months, P = .439). When comparing patients receiving non‐PBC doublets (n = 221) with those receiving PBC doublets (n = 249), the same trend was observed in ORR (32.6% vs 53.0%, P < .001), median first‐line PFS (6.5 vs 8.4 months, P = .041) and median first‐line OS(17.8 vs 19.2 months, P = .568). Paclitaxel/docetaxel + platinum was more likely to be used, followed by gemcitabine + platinum. In second/third‐line treatment, PBC yielded a similar response and survival compared to non‐PBC. Adding PBC in the first‐line therapy was better than that in the latter‐line of treatment in terms of ORR, PFS and OS (P < .001). Toxic effects of PBC were tolerable and the most common adverse event was neutropenia (38.6%). PBC doublets exhibited superior efficacy and manageable toxicity compared to non‐PBC doublets in the first‐line treatment for Chinese mTNBC patients.

• Publication year

  2020

• Venue

  International Journal of Cancer

• Publication date

  2020-06-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ijc.33175PMID 32588429
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Breast Cancer Treatment: A Review

  2019influential reference
• Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.

  2019cited by this paper
• Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis

  2018cited by this paper
• Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

  2018cited by this paper
• Platinum-containing regimens for metastatic breast cancer.

  2017cited by this paper
• Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.

  2017cited by this paper
• Drug Delivery Strategies for Platinum-Based Chemotherapy.

  2017cited by this paper
• Platinum containing regimens for metastatic breast cancer.

  2017cited by this paper
• Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial

  2017cited by this paper
• Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy

  2015cited by this paper
• Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.

  2015cited by this paper
• Efficacy of platinum-based chemotherapy in triple-negative breast cancer patients with metastases confined to the lungs: a single-institute experience

  2014cited by this paper
• Efficacy of biological agents in metastatic triple-negative breast cancer.

  2014influential reference
• Platinum-based chemotherapy in triple-negative advanced breast cancer

  2014cited by this paper
• Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer.

  2013cited by this paper
• Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience.

  2011cited by this paper
• Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.

  2010cited by this paper
• Triple-negative breast cancer.

  2010cited by this paper
• Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients.

  2010cited by this paper
• Treatment outcomes and clinicopathologic characteristics of triple‐negative breast cancer patients who received platinum‐containing chemotherapy

  2009cited by this paper
• Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.

  2009cited by this paper
• 41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple-negative

  2009cited by this paper
• A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.

  2008cited by this paper
• Platinum-based chemotherapy in triple-negative breast cancer.

  2008cited by this paper
• Basal-like breast cancer and the BRCA1 phenotype

  2006cited by this paper
• BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.

  2003cited by this paper

• Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial

  2025cites this paper
• Analysis of survival differences in advanced triple-negative breast cancer: a real-world study

  2025cites this paper
• Guidelines for the Diagnosis and Treatment of Advanced Breast Cancer in China (2024 Edition)

  2025cites this paper
• Guidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)

  2023cites this paper
• Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer

  2023cites this paper
• Real-World Study: A Powerful Tool for Malignant Tumor Research in General Surgery

  2022cites this paper
• KẾT QUẢ HÓA TRỊ PHÁC ĐỒ CHỨA PLATIN TRONG ĐIỀU TRỊ UNG THƯ BIỂU MÔ TUYẾN VÚ CÓ BỘ BA ÂM TÍNH TÁI PHÁT DI CĂN

  2022cites this paper
• Assessment of antitumor activity of BP-C1, a platinum-based anticancer agent with a lignin-derived polymeric ligand, in autochthonous induced and spontaneous carcinogenesis rodent models.

  2022cites this paper
• A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer

  2022cites this paper
• Platinum-based systematic therapy in triple-negative breast cancer.

  2022cites this paper
• Survival benefit of platinum-based regimen in early stage triple negative breast cancer: A meta-analysis of randomized controlled trials

  2021cites this paper
• Treatment-associated survival outcomes in real-world patients with de novo metastatic triple-negative breast cancer: Age as a significant treatment effect-modifier.

  2021cites this paper
• Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials

  2021cites this paper
• The Shuganhuazheng Formula in Triple-Negative Breast Cancer: A Study Based on Network Pharmacology and In Vivo Experiments

  2020cites this paper